Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Monolithic Power Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Monolithic Power Systems Inc trades at $1,315 (market cap $66.46B). The key difference: Monolithic Power Systems Inc is the larger of the two by market cap, and Monolithic Power Systems Inc pays a 0.59% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MPWR | |
|---|---|---|
Market Cap | $39.89B | $66.46B |
Sector | Health | Utilities |
52-Week High | $491.22 | $1.69K |
52-Week Low | $278.09 | $711.24 |
Enterprise Value | $38.15B | $65.11B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MPWR trades at $1,352.74, down 1.56% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company demonstrates strong profitability with a 22.98% net income margin and consistent earnings beats in recent quarters. Analyst sentiment is overwhelmingly positive with 88% buy ratings and a consensus price target of $1,760. Recent news highlights ongoing investigations into corporate governance alongside positive coverage of AI infrastructure growth opportunities.
The outlook for MPWR remains favorable given its earnings momentum and positioning in AI and power management semiconductors. Key opportunities include expanding demand in data centers and telecom, while risks involve high valuation multiples and corporate governance scrutiny. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
